Once you memorize these API-580 test questions, you will get 100% marks.

We regarded with our acknowledgment of assisting individuals with breezing through the Risk Based Inspection Professional assessment of their absolute first endeavor with our most recent, legitimate, and exceptional API-580 test questions and replies. Our prosperity during the beyond two years has been totally heavenly, Thanks to our happy clients who are presently ready to get advancements in their individual associations. killexams.com is the main decision among certificate experts.

Exam Code: API-580 Practice test 2022 by Killexams.com team
Risk Based Inspection Professional
API Professional certification
Killexams : API Professional certification - BingNews https://killexams.com/pass4sure/exam-detail/API-580 Search results Killexams : API Professional certification - BingNews https://killexams.com/pass4sure/exam-detail/API-580 https://killexams.com/exam_list/API Killexams : API series - Postman: 7-habits of effective API-first orgs

This is a guest post for the Computer Weekly Developer Network written by Kin Lane in his role as chief evangelist at Postman, an API platform used by more than 20 million developers and 500,000 organisations for building and using APIs.

Lane writes as follows…

Airbnb. PayPal. Stripe. Uber. Amazon Web Services, Google Cloud and Microsoft Azure.

These are just a sample of the groundbreaking technology companies that would not exist without Application Programming Interfaces (APIs). These brands have built their businesses on the ubiquitous digital interfaces that enable different software applications to interact with one another.

But while APIs already have been powering much of the world around us, more and more large enterprises of all types are realising they can’t really be digital without an API-first philosophy.

What is an API-first company? It understands that delivering applications through a mix of internal and external services using APIs is critical to digital transformation – and it adopts a strategy and set of processes that treat APIs as the fundamental business assets they are.

The reasons for becoming an API-first company aren’t just technical, so interest in API-first among business leaders is soaring. This explains why not only developers but also product managers, security engineers, and customer support teams, among others, are now working with APIs.

Yet, despite all that interest and awareness, the subject is sometimes misunderstood. API-first can mean different things to different people. This can generate anxiety and confusion as organisations consider what qualifies as an API-first approach and how to proceed.

The question today isn’t so much whether companies are ‘doing’ APIs – they almost certainly are – but whether they’re doing them well.

So, what makes a successful API-first organisation? It boils down to possessing these seven essential traits.

#1 A comprehensive strategy

More companies across almost every business sector are recognising not just the value of connecting internal, partner and public APIs but the need to have a solid strategy for how contributors, consumers, and other stakeholders can interact with an API at different stages of its lifecycle, including planning, design, test, deployment, and versioning.

Each one of us makes thousands of API calls a day in the course of our personal and professional lives. But despite this, many organisations still lack a formal strategy for defining how APIs will be designed, developed, delivered and operated – and that is just for the APIs that the companies build – there are hundreds of other partner and third-party APIs they depend on that lack a strategy as well.

Amazing, right? Fact is, there is no way to remain competitive unless companies have a formal strategy for how APIs work across the organisation. That is the first step toward being API-first.

#2 A holistic view

For the past two decades, organisations have raced to stitch together a dizzying array of applications and systems for their operations, and now they’re increasingly developing their own web, mobile, and device applications on top of it all. All of these new applications rely on APIs, and that often leads to a redundant and chaotic mix of APIs.

Being API-first means prioritising all of the APIs behind applications and considering them as a whole, accounting for how they will be used across all applications, rather than just scrambling to deliver a single application that often leaves vulnerable and redundant APIs in their shadows.

#3 Attention to discovery & visibility

In a perfect world, every organisation publishes their APIs to an internal, partner, or public catalogue. In the real world, very few enterprise organisations even know where all of their APIs are.

Being API-first means that all APIs are prioritised and discoverable by default. This saves time and resources by eliminating redundancy and waste across companies’ vast expanse of APIs.

Without being API-first, companies simply won’t have the visibility across their operations to understand where consistency exists or doesn’t in the design of an API as well as the supporting documentation, testing, security, and monitoring of APIs.

#4 Commitment to quality

Postman’s Lane: 7-pointers for API appointment.

Lack of quality across its API ecosystem affects a company’s bottom line in two ways – through loss of business and through time spent troubleshooting, fixing, and responding to preventable incidents.

Being API-first raises the bar on the need for API quality. Teams must be equipped with the training and tooling they need to develop and apply modular testing across every API they produce or consume.

#5 Focus on strong security

Being API-first means that every API and microservices has security protection that is centrally defined by security experts and then also applied by developers as part of the regular API development lifecycle.

Even the simplest of APIs are put through the minimum security scanning and evaluation as they are being deployed or changed with each new version. Security is consistently applied across all APIs used by teams, no matter what the application is or how long the API will be used by consumers.

Companies need those practices if they are to feel confident in opening up access to their digital resources to partners and third-party developers.

#6 Strong internal processes

An API-first approach means establishing familiar and easily accessed workspaces where API work is centralised. They should contain artifacts, documentation, mock servers, environments, tests, monitors, history, and everything else new and existing team members need.

Repeatable processes are established in order to optimise the design, development, deployment, and operation of APIs and microservices. Rough edges of the API lifecycle are smoothed out across teams, which are equipped with the knowledge and tooling they need to consistently deliver and iterate upon APIs.

In an API-first organisation, these kinds of processes matter. They foster the teamwork needed to innovate.

7 – Reliance on open standards

Complex and non-standardised APIs require more resources to onboard and integrate with, resulting in friction throughout the life of an API. But use of common standards reduces the cognitive load needed to understand what an API does, and they increase the likelihood that there will be common open source libraries and tooling available when producing or consuming APIs.

Using standards as part of an API-first approach makes good business sense: It increases productivity, quality, and velocity across any API, catering to the widest possible number of consumers in each industry.

By modeling themselves after these seven characteristics, companies can make sure they’re on an API-first journey that drives the business forward, saves time and money, and, ultimately, spells the difference between remaining competitive or falling behind.

In today’s digital landscape, every organisation should seek to be API-first so they don’t end up API-last.

Tue, 22 Nov 2022 22:18:00 -0600 en text/html https://www.computerweekly.com/blog/CW-Developer-Network/API-series-Postman-7-habits-of-effective-API-first-orgs
Killexams : Australian application teams are now reviewing whether their APIs overshare

GUEST OPINION: The world has become increasingly reliant on software to make everything work, and application programming interfaces (APIs) play a key role in that. Whether seeking a weather update, participating in an online event, collaborating with colleagues, or engaging in a telehealth consultation, APIs enable software components to talk to each other in the background to both make user requests and respond to them.

As a result, APIs have exploded in popularity as the default way to connect or otherwise communicate with applications, such as to query information held by enterprise systems. The number of companies working with public APIs almost doubled between 2019 and 2022, while use of other API types—internal, private or third-party—now exceeds 90% in all cases.

API management needs a critical shift
As API sprawl and usage grows, management of this vast field of connections is not keeping pace. Gartner’s prediction is that “by 2025, less than 50% of enterprise APIs will be managed, as explosive growth in APIs surpasses the capabilities of API management tools.” As the world becomes API-centric, that lack of management will create security challenges.

This is already evident: Gartner predicted last year that API attacks would become the most frequent attack vector in 2022, “causing data breaches for enterprise web applications.” On this, they were correct.

A publicly exposed API is widely believed to be the cause of at least one of the major attacks on Australian enterprises in the back half of 2022, attacks that have collectively driven significant policy reform from government and reviews of cybersecurity posture on the part of other Australian enterprises.

And Australia isn't alone. Worldwide, around three-quarters of enterprises reported experiencing an API security incident in the last year. In a similar proportion of companies, cybersecurity professionals “did not have a complete API inventory or know which APIs returned sensitive data”. In 62% of organisations, one-third or more of APIs are undocumented.

Coupling this with the fact that “only 11% of respondents test APIs for signs of abuse in real-time”, there are substantial danger signs that APIs can be used and abused to leak data, and that very few organisations would pick up the problem in a timely manner, before it ballooned into something far more damaging.

Training, supported by an architectural rethink, is the key
By design, APIs open the floodgates for communication between apps. It's possible to have too much talking between APIs which will overshare "too much information" if that is made permissible.

In addition, when the risk-mitigation measures for API access control are lax, APIs will reveal too much information or—worse—expose themselves through a vulnerable app backdoor. Too often, developers over-permission APIs for functions so they don't have to keep changing access rights with every program build. However, attackers are well aware that this is happening, so they seek to breach APIs and use their powerful permissions to infiltrate networks.

To effectively mitigate against these challenges and attack risks, organisations need to train their developers on "security first" while subjecting APIs to least-privilege Zero Trust policies

How to strengthen API security
First, organisations should work to upskill developers to cultivate a "security first" culture. Security first and other so-called ‘shift-left’ approaches seem to bring a security mindset into everything a developer produces. It's critical to educate developers about the nuances that differentiate a poor coding pattern from a good one, to help them focus on building safe software from the start.

In addition, when security teams strengthen their communications and relationships with developers, those developers learn how to use the right tools for protection and even maximise their value. Hands-on/person-to-person training is essential here. Computer-based training by itself comes with too many limitations, often lacking the ability to verify the security skills of participants. Organisations and security teams need assurance that the knowledge has stuck and is being implemented correctly as part of the software development lifecycle.

Practising real-life scenarios can assist in this regard. Developers benefit the most by experiencing the real-world scenarios and consequences of broken access control—it's the most potent way to both verify and Improve skills, and all training programs must include this if they are to be successful.

Outside of specific training, security and development teams are advised to extend the concept of Zero Trust to APIs. We typically consider Zero Trust in terms of user access—controlling how people authenticate to the corporate network, and what they are then permitted to do. Organisations should apply Zero Trust to APIs as well to eliminate over-permissioning and enforce role-based controls. If an API is supposed to perform a specific function, then security teams must work with developers to restrict permissions to solely that function.

In further incorporating Zero Trust, security and/or developer teams are advised to limit the calls APIs are allowed to make, so these calls are strictly conducted based upon context-centred requests. Subsequently, attackers will encounter difficulties in modifying them for criminal purposes.

The road forward
APIs are going to remain a vital part of today’s interconnected world. Their ability to request and receive data from other sources means they underpin a significant portion of online transactions.
As API security shifts, it’s crucial for developers to understand their role in keeping APIs secure.

Tue, 13 Dec 2022 08:49:00 -0600 en-gb text/html https://itwire.com/guest-articles/guest-opinion/australian-application-teams-are-now-reviewing-whether-their-apis-overshare.html
Killexams : Wib pioneers industry-first API PenTesting-as-a-Service No result found, try new keyword!Wib, the fast-growing cybersecurity startup pioneering a new era in API security, today announced an industry-first API PenTesting-as-a-Service (PTaaS) designed to help organizations proactively cover ... Tue, 29 Nov 2022 20:46:00 -0600 en-US text/html https://it.tmcnet.com/news/2022/11/30/9721565.htm Killexams : Why is Robust API Security Crucial in eCommerce?

API attacks are on the rise. One of their major targets is eCommerce firms like yours.

APIs are a vital part of how eCommerce businesses are accelerating their growth in the digital world.

ECommerce platforms use APIs at all customer touchpoints, from displaying products to handling shipping. Owing to their increased use, APIs are attractive targets for hackers, as the following numbers expose:

  • API attack traffic increased by 681% in 2021
  • 77% of retail respondents experienced API security incidents in 2021– according to Noname security

If left unaddressed, API abuse can damage your reputation, harm consumers, and affect the bottom line. Hence API security is worthy of consideration for eCommerce stakeholders.

Why do eCommerce companies need APIs?

API makes it easy for retailers and eCommerce platforms to handle product listings and orders. It transformed the static website into a completely customizable headless store. Retailers use APIs for various functions, including login, product catalog, shipping, and subscription.

It empowers businesses to enhance customer experience. While making purchases, one service handles orders; another calculates tax; another enables shipping, and so on.

But customers have no idea what is happening behind the screen. API connects these decoupled elements and helps to share data seamlessly.

Key benefits of APIs in eCommerce

  • It streamlines operations and ensures seamless customer engagements
  • It is effective for data monitoring and analytics, a vibrant factor for retailers
  • It enables communication with chatbots
  • Connects eCommerce platform with 3rd party marketplaces

Why Is API Security Crucial for Ecommerce?

APIs are easy to use and integrate for businesses. Even though most APIs are not intended for public use, they often have full access to all sensitive assets and information.

Customers enter PII while purchasing on online sites like emails, passwords, credit card details, and phone numbers. They also share transaction details like bonuses, balances, and rewards. This increases the opportunity for attackers to steal the data.

They are easy to expose if not designed and tuned for robust, ongoing security. Inadequate security testing and a lack of business logic have resulted in an overall rise in API security risks.

Important factors that drive API security concerns are

Authentication Flaw

Many APIs not properly checking if the request comes from a legitimate user. Hackers find coding errors in authentication and escalate privileges. They further use enumerated technologies to compromise users' accounts.

For instance, some eCommerce platforms integrate with external logistics systems to pass on shipping details. In this situation, if there is an insufficient authentication chain, API can leak PII via replay attacks.

Automated Attacks

Automated attacks on insecure APIs are increasing with the widespread adoption of APIs. Rather than exploiting vulnerabilities in APIs code, hackers exploit business logic flaws within APIs.

They may feed malicious scripts into bots to access your product details at scale.

With bad bots overwhelming your site, your genuine user cannot shop on your site. For example, they can snatch the complete inventory of high-demand products within seconds.

Volumetric attacks against eCommerce API without rate limiting (#4 in OWASP API Security Top 10) can cause shopping apps non-responsive, resulting in user dissatisfaction.

Shadow and Zombie APIs

Still, many businesses struggle to separate real transactions from fake. They are also blindsided by unprotected shadow APIs.

Equally, Zombie APIs are the most common method of attack. Zombie APIs may longer be unmonitored. They can contain malicious codes or may expose sensitive data or functionality.

Third-party APIs

E-commerce businesses integrate with 3rd parties like shipping and payment systems. Third-party APIs are challenging to manage. These are the ones that attackers typically target.

For example, shopping cart API is a prime target as it offers entry points into the business. A leading UK retailer experienced attacks more than 1000 times a day on this API. The attack increased 10-fold times when special offers were running.

Traditional Security Tools

Most businesses lack adequate defense capabilities to protect against the ever-evolving API risks. API threats are highly sophisticated and persistent, and traditional methods are ineffective against them.

Legacy WAF or API gateways need more real-time ability to understand bad from good API activity.

Hackers can manipulate the discount and promotion APIs during peak times. These tools find it hard to protect against such attacks.

You will need comprehensive API protection solutions like AppTrana to protect your website and customers' sensitive information.

API Security Best Practices for Ecommerce

The API threats to eCommerce security are potentially devastating to retailers and customers. For this reason, you must take appropriate measures to address them.

API Discovery

The first step is to understand what you have in your API landscape. An inventory of all APIs, including undocumented APIs, is essential if you want to secure what you don't know about.

API discovery involves finding and inventorying APIs. 67% of the retail respondents say they lack visibility on API inventory. A good API security solution offers strong API discovery features. It automatically inventories all APIs, including Zombie and shadow APIs.

Make sure zombie APIs are turned off. After the last customer stops integrating with a deprecated API, ensure the API is turned off. If you're going to publish API documentation externally, make sure it's valid and tested, and it's not exposing vulnerabilities.

API Security Testing and Penetration Testing

Integrate API security at the early stage of the development process. Security enhancement and vulnerability management are key aspects of your API development. Use API security scanners (e.g., Infinite API Scanner) for smooth API vulnerability scans. Make sure to patch the identified vulnerabilities immediately.

In addition to automated API scanning tools, manual pen testing is vital. It helps you to detect misconfiguration that could otherwise go unseen.

Proper Authentication and Authorization

Validating purchasers who they are and only allowing access to specific resources they have permission for is essential in API security.

OAuth 2.0, API keys, and Token based authentication are a few API authentication methods to verify users' identity.

API Rate Limiting

According to data, there were 28 API endpoints in 2020 and 89 in 2021, a three-fold increase in API endpoints. A similar increase in API calls is logical. There was a 141% increase in API calls in H1 2021. There has been a corresponding increase in attack surfaces.

Attackers can make eCommerce sites unavailable for legitimate purchasers with DDoS attacks. With API rate limiting, you can limit the number of requests from overwhelming system resources. It can throttle the request that exceeds the limits. It enables you to make your site available for purchasers without impacting performance.

API Behaviour and Analytics

Leverage API protection solution to look for abnormal behaviour in API traffic. Differentiating malicious traffic from normal API traffic can help to detect attacks in progress.

It also highlights system misbehaviors and other malicious disruptions to your service. It analyzes traffic metadata to pinpoint the attack source. You can use this information to stop the incident and fix the issue in API.

Tips to protect your eCommerce Site

  • Make sure all third-party integrations and plugins are regularly inspected
  • Help your customers to create strong, unique passwords
  • Ensure that only necessary customer data is stored
  • Always keep your site up-to-date
  • Secure your website with HTTPS
  • Keep a backup of your data

Ecommerce Security: Plan Ahead to Stay Safe

An increase in API usage has increased the attack surface, which leaves eCommerce businesses vulnerable. It calls for the immediate requirement to mitigate the API security risks mentioned above.

Failing to secure an eCommerce platform can directly impact sales. It ruins your reputation. Take immediate measures to win your API security platform.


Found this article interesting? Follow us on Twitter and LinkedIn to read more exclusive content we post.
Thu, 08 Dec 2022 23:48:00 -0600 en text/html https://thehackernews.com/2022/12/why-is-robust-api-security-crucial-in.html
Killexams : API Management Market Size to Surpass Around USD 46.74 Bn by 2030

Ottawa, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Recently Published Report on "API Management Market (By Component, By Deployment, By Organization Size, By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030".

As the organizations and businesses that deal with critical data and critical activities have increased the adoption of API management in their businesses the market is expected to generate good amount of revenue in the coming years.

There were major changes in the supply chains ever since the pandemic has hit the countries. In order to overcome the disruptions of the supply chain API management was adopted on a large scale by many organizations across the globe. As it assists in handling various situations that are real time and it provides information for better decision making the market will continue to grow in the coming years.

Get the sample copy of this report@ https://www.precedenceresearch.com/sample/2432

Regional snapshots

There shall be an increased demand for API management in the Asia Pacific region. As many digital initiatives are undertaken by the government in the Asia Pacific region the demand for this platform will continue to grow in the coming years. Many organizations in this region are making investments for incorporating these technologies for enhancing the business procedures. As many small scale and medium scale industries are present in the Asia Pacific region which makes 96% of overall business in this region there shall be an increased adoption of API technologies in the coming years.

Report highlights

  • Solution segment will dominate the market in the coming year. There is an increased adoption of solutions to enhance the experience for the consumers and the providers. Attempts in providing an environment that is secure for the growth of the market in the coming years. The other subsegments of solutions our API security, analytics and API platform.
  • On the basis of services, the implementation and the integration subsegment will grow well in the coming years by understanding the needs of the system that the client has been using and the understanding of the infrastructure in place the provider needs to integrate features as per the requirements. And there shall be an increased demand for these services in the coming years as they are beneficial in driving the growth of the market without hampering the operations of the business
  • On the basis of deployment, on premises segment will dominate the market in the coming years. Large scale industries that make use of these solutions invest for procuring the on-premise setup. The organizations that deal with critical information about the users need this type of model in order to enhance their security. It goes up the adoption of on-premise set-up is expensive as though huge amount of cost associated with acquiring the infrastructure and the device is needed for the execution.
  • On the basis of the organizations size, the large enterprises will have a larger demand for this technology. These organizations invest a lot of amount in acquiring latest technology. The rate at which these solutions will be adopted by the large-scale industries will be more as compared to the other industries in the market.
  • The financial and the banking industry shall make use of these solutions on a large scale. As these industries deal with crucial information about the consumers there is a growing need for this platform. It helps in providing a better experience to its bankers and it provides an enhanced experience for the customers. Each other as this model is cost effective the market will continue to grow and its adoption will increase for various sectors in the coming years. It will also be used in other industries like transportation as well as retail and consumer goods.

Recent developments

  • Google entered into a partnership with automation anywhere in the year 2021 and this partnership has introduced intelligent capabilities in automation for the different types of business processes.

Ask here for more customization study@ https://www.precedenceresearch.com/customization/2432

Scope of the Report

Report Attributes Details
Market Size in 2022 USD 5.37 Billion
Revenue Forecast by 2030 USD 46.74 Billion
CAGR 31.05% from 2022 to 2030
Largest Market North America
Fastest Growing Region Asia Pacific
Base Year 2022
Forecast Year 2022 to 2030
Key Players Google (US), IBM (US), Microsoft (US), Axway Software (US), Broadcom Inc. (US) and Others

Market dynamics

Drivers

Many organizations across the globe are adopting API management for better decision making which is based on the information available with the organizations. API management has been instrumental in providing and intermediary service for the external and the internal users and the data consumers. The use of this platform has increased the flexibility and the user experience provided by the organizations to its users. By making use of solutions that help in monitoring the data and protecting the data which is encrypted with the use of signatures the market is expected to grow in the coming years. The security of the system is maintained with the use of this technology and the data available with the organizations is safe. This platform has been instrumental in checking any vulnerabilities with the network. All the applications are unified with the help of this platform and all of these factors will drive the market growth during the forecast period

Restraints

It is very important to understand the stability quality as well as the flexibility of the API for any organization that wishes to implement the API management in their infrastructure. there is a need for a skilled developer for the installation of API management platform in any organization who has correct knowledge of the software and is aware of the current trends in the market. A lot of time is invested in acquiring this professional and also for the persons training. Wide range of expertise is required for its infrastructure and implementation and all of these factors will hamper the growth of the market during the forecast period.

Opportunities

many organizations in the developing as well as the developed nations I understood the significance of using the software as it helps in increasing the growth of the organization. As these platforms are low code platforms its optimization and implementation will be easier and it shall provide better opportunities for growth during the forecast period. It also enhances the security and helps in reducing the risk of cyber-attacks. All of these factors will provide better opportunities for growth during the forecast period. All different types of organizations like small scale medium scale and large scale will benefit due to the use of this platform in the coming years period

Challenges

The API management solution needs to be assessed in order to support the multi-cloud services. That it needs a central control for different regions and different clouds. The introduction of the management platform which makes use of multiple clouds will be a challenging factor in the growth of the market.

Related Reports

Get Our Latest Press Releases@ https://www.precedenceresearch.com/press-releases

Market Segmentation

By Component

By Deployment

By Organization Size

  • Large Enterprises
  • Small and Medium Enterprises

By End User

  • Banking and Financial Institutes
  • Retail
  • IT and Telecommunications
  • Consumer Goods
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Immediate Delivery Available | Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/2432

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com  | +1 9197 992 333

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

https://twitter.com/Precedence_R


© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Wed, 07 Dec 2022 00:00:00 -0600 text/html https://www.benzinga.com/pressreleases/22/12/g29992395/api-management-market-size-to-surpass-around-usd-46-74-bn-by-2030
Killexams : Biological API Drug Manufacturing Market 2023 In-Depth Insights and Business Scenario, by Analysts Certification 2028 | Newst 121 Pages Report

The MarketWatch News Department was not involved in the creation of this content.

Nov 16, 2022 (The Expresswire) -- |Final Report will be add after Pre and Post COVID-19 Impact | Detailed 174 Tables and Figures | Premium Research Report | newest Data Insights |

[121 Pages No.] Biological API Drug Manufacturing Market report are massive business with critical facilities designed to efficiently support robust opportunities, scalable applications and are often associated with big data-producing companies such as Facebook, Instagram, Google, LinkedIn, Twitter, Pinterest, Tumblr,. The use of Biological API Drug Manufacturing Market is opening new frontiers across the IIII industry. With the ability to manipulate matters, Biological API Drug Manufacturing market has huge potential to revolutionize segment aspects of Types (Content Marketing, Traditional Advertising,), Applications (BFSI, Manufacturing, Healthcare, IT And ITES, Utilities, Others,). Biological API Drug Manufacturing industry report offers an inclusive analysis of Biological API Drug Manufacturing size market size in business plan across the globe as regional and country level, developing the cooperative, provides a detailed analysis, come again is the up-to-date market scope of the Biological API Drug Manufacturing market 2023.

Biological API Drug Manufacturing Market - Covid-19 Impact and Recovery Analysis:

We have been tracking the direct impact of COVID-19 on this market, as well as the indirect impact from other industries. This report analyzes the impact of the pandemic on the Biological API Drug Manufacturing market from a Global and Regional perspective. The report outlines the market size, market characteristics, and market growth for Biological API Drug Manufacturing industry, categorized by type, application, and consumer sector. In addition, it provides a comprehensive analysis of aspects involved in market development before and after the Covid-19 pandemic. Report also conducted a PESTEL analysis in the industry to study key influencers and barriers to entry.

Final Report will add the analysis of the impact of COVID-19 on this industry.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT - REQUEST SAMPLE

It also provides accurate information and cutting-edge analysis that is necessary to formulate an ideal business plan, and to define the right path for rapid growth for all involved industry players. With this information, stakeholders will be more capable of developing new strategies, which focus on market opportunities that will benefit them, making their business endeavours profitable in the process.

Biological API Drug Manufacturing Market - Competitive and Segmentation Analysis:

This Biological API Drug Manufacturing Market report offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2017-2023. The report also includes company description, major business, Biological API Drug Manufacturing product introduction, latest developments and Biological API Drug Manufacturing sales by region, type, application and by sales channel.

The major players covered in the Biological API Drug Manufacturing market report are:

● Lonza ● Boehringer Ingelheim BioXcellence ● Celltrion ● DSM ● Samsung BioLogics ● Fujifilm Diosynth Biotechnologies ● Cytovance Biologics ● AbbVie ● Baxter ● CEPiA Sanofi ● GSK ● Pfizer CentreOne ● Sandoz ● Vetter ● Wuxi Biologics

Get a sample PDF of report - https://www.360marketupdates.com/enquiry/request-sample/21938964

Short Summery About Biological API Drug Manufacturing Market:

The Global Biological API Drug Manufacturing market is anticipated to rise at a considerable rate during the forecast period, between 2023 and 2028. In 2023, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

It is an API produced by human, animal, microbial, genetic engineering or changing its source and through fermentation, bacterial culture, biotechnology and subsequent purification processes.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Biological API Drug Manufacturing estimated at USD million in the year 2022, is projected to reach a revised size of USD million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Biological API Drug Manufacturing is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Biological API Drug Manufacturing is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Biological API Drug Manufacturing is estimated to increase from USD million in 2022 to reach USD million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Biological API Drug Manufacturing include Lonza, Boehringer Ingelheim BioXcellence, Celltrion, DSM, Samsung BioLogics, Fujifilm Diosynth Biotechnologies, Cytovance Biologics, AbbVie and Baxter, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
In terms of production side, this report researches the Biological API Drug Manufacturing production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Biological API Drug Manufacturing by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.
Report Scope
This latest report researches the industry structure, capacity, production, sales (consumption), revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Biological API Drug Manufacturing manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Biological API Drug Manufacturing market. Further, it explains the major drivers and regional dynamics of the global Biological API Drug Manufacturing market and current trends within the industry.

Report further studies the market development status and future Biological API Drug Manufacturing Market trend across the world. Also, it splits Biological API Drug Manufacturing market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

On the basis of product typethis report displays the production, revenue, price, market share and growth rate of each type, primarily split into:

● In-House manufacturing ● Contract manufacturing

On the basis of the end users/applicationsthis report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including:

● Monoclonal Antibody (mAb) Therapies ● Vaccines ● Insulin Therapies ● Interferon Therapies ● Other

Get a sample Copy of the Biological API Drug Manufacturing Market Report 2023

Biological API Drug Manufacturing Market - Regional Analysis:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Biological API Drug Manufacturing in these regions, from 2015 to 2028, covering

● North America (United States, Canada and Mexico) ● Europe (Germany, UK, France, Italy, Russia and Turkey etc.) ● Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam) ● South America (Brazil, Argentina, Columbia etc.) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

{174 Tables and Figures, Data Insights are covered in this Report}

Some of the key questions answered in this report:

● What is the global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) sales value, production value, consumption value, import and export of Biological API Drug Manufacturing? ● Who are the global key manufacturers of the Biological API Drug Manufacturing Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)? ● What are the Biological API Drug Manufacturing market opportunities and threats faced by the vendors in the global Biological API Drug Manufacturing Industry? ● Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application? ● What focused approach and constraints are holding the Biological API Drug Manufacturing market? ● What are the different sales, marketing, and distribution channels in the global industry? ● What are the upstream raw materials and manufacturing equipment of Biological API Drug Manufacturing along with the manufacturing process of Biological API Drug Manufacturing? ● What are the key market trends impacting the growth of the Biological API Drug Manufacturing market? ● Economic impact on the Biological API Drug Manufacturing industry and development trend of the Biological API Drug Manufacturing industry. ● What are the market opportunities, market risk, and market overview of the Biological API Drug Manufacturing market? ● What are the key drivers, restraints, opportunities, and challenges of the Biological API Drug Manufacturing market, and how they are expected to impact the market? ● What is the Biological API Drug Manufacturing market size at the regional and country-level?

Our research analysts will help you to get customized details for your report, which can be modified in terms of a specific region, application or any statistical details. In addition, we are always willing to comply with the study, which triangulated with your own data to make the market research more comprehensive in your perspective.

Inquire more and share questions if any before the purchase on this report at -https://www.360marketupdates.com/enquiry/pre-order-enquiry/21938964

Detailed TOC of Global Biological API Drug Manufacturing Market Research Report 2023

1 Biological API Drug Manufacturing Market Overview

1.1 Product Overview and Scope of Biological API Drug Manufacturing
1.2 Biological API Drug Manufacturing Segment by Type
1.2.1 Global Biological API Drug Manufacturing Market Size Growth Rate Analysis by Type 2023 VS 2028
1.3 Biological API Drug Manufacturing Segment by Application
1.3.1 Global Biological API Drug Manufacturing Consumption Comparison by Application: 2023 VS 2028
1.4 Global Market Growth Prospects
1.4.1 Global Biological API Drug Manufacturing Revenue Estimates and Forecasts (2017-2028)
1.4.2 Global Biological API Drug Manufacturing Production Capacity Estimates and Forecasts (2017-2028)
1.4.3 Global Biological API Drug Manufacturing Production Estimates and Forecasts (2017-2028)
1.5 Global Market Size by Region
1.5.1 Global Biological API Drug Manufacturing Market Size Estimates and Forecasts by Region: 2017 VS 2021 VS 2028
1.5.2 North America Biological API Drug Manufacturing Estimates and Forecasts (2017-2028)
1.5.3 Europe Biological API Drug Manufacturing Estimates and Forecasts (2017-2028)
1.5.4 China Biological API Drug Manufacturing Estimates and Forecasts (2017-2028)
1.5.5 Japan Biological API Drug Manufacturing Estimates and Forecasts (2017-2028)

2 Market Competition by Manufacturers
2.1 Global Biological API Drug Manufacturing Production Capacity Market Share by Manufacturers (2017-2023)
2.2 Global Biological API Drug Manufacturing Revenue Market Share by Manufacturers (2017-2023)
2.3 Biological API Drug Manufacturing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.4 Global Biological API Drug Manufacturing Average Price by Manufacturers (2017-2023)
2.5 Manufacturers Biological API Drug Manufacturing Production Sites, Area Served, Product Types
2.6 Biological API Drug Manufacturing Market Competitive Situation and Trends
2.6.1 Biological API Drug Manufacturing Market Concentration Rate
2.6.2 Global 5 and 10 Largest Biological API Drug Manufacturing Players Market Share by Revenue
2.6.3 Mergers and Acquisitions, Expansion

3 Production Capacity by Region
3.1 Global Production Capacity of Biological API Drug Manufacturing Market Share by Region (2017-2023)
3.2 Global Biological API Drug Manufacturing Revenue Market Share by Region (2017-2023)
3.3 Global Biological API Drug Manufacturing Production Capacity, Revenue, Price and Gross Margin (2017-2023)
3.4 North America Biological API Drug Manufacturing Production
3.4.1 North America Biological API Drug Manufacturing Production Growth Rate (2017-2023)
3.4.2 North America Biological API Drug Manufacturing Production Capacity, Revenue, Price and Gross Margin (2017-2023)
3.5 Europe Biological API Drug Manufacturing Production
3.5.1 Europe Biological API Drug Manufacturing Production Growth Rate (2017-2023)
3.5.2 Europe Biological API Drug Manufacturing Production Capacity, Revenue, Price and Gross Margin (2017-2023)
3.6 China Biological API Drug Manufacturing Production
3.6.1 China Biological API Drug Manufacturing Production Growth Rate (2017-2023)
3.6.2 China Biological API Drug Manufacturing Production Capacity, Revenue, Price and Gross Margin (2017-2023)
3.7 Japan Biological API Drug Manufacturing Production
3.7.1 Japan Biological API Drug Manufacturing Production Growth Rate (2017-2023)
3.7.2 Japan Biological API Drug Manufacturing Production Capacity, Revenue, Price and Gross Margin (2017-2023)

4 Global Biological API Drug Manufacturing Consumption by Region
4.1 Global Biological API Drug Manufacturing Consumption by Region
4.1.1 Global Biological API Drug Manufacturing Consumption by Region
4.1.2 Global Biological API Drug Manufacturing Consumption Market Share by Region
4.2 North America
4.2.1 North America Biological API Drug Manufacturing Consumption by Country
4.2.2 United States
4.2.3 Canada
4.3 Europe
4.3.1 Europe Biological API Drug Manufacturing Consumption by Country
4.3.2 Germany
4.3.3 France
4.3.4 U.K.
4.3.5 Italy
4.3.6 Russia
4.4 Asia Pacific
4.4.1 Asia Pacific Biological API Drug Manufacturing Consumption by Region
4.4.2 China
4.4.3 Japan
4.4.4 South Korea
4.4.5 China Taiwan
4.4.6 Southeast Asia
4.4.7 India
4.4.8 Australia
4.5 Latin America
4.5.1 Latin America Biological API Drug Manufacturing Consumption by Country
4.5.2 Mexico
4.5.3 Brazil

Get a sample Copy of the Biological API Drug Manufacturing Market Report 2023

5 Segment by Type
5.1 Global Biological API Drug Manufacturing Production Market Share by Type (2017-2023)
5.2 Global Biological API Drug Manufacturing Revenue Market Share by Type (2017-2023)
5.3 Global Biological API Drug Manufacturing Price by Type (2017-2023)
6 Segment by Application
6.1 Global Biological API Drug Manufacturing Production Market Share by Application (2017-2023)
6.2 Global Biological API Drug Manufacturing Revenue Market Share by Application (2017-2023)
6.3 Global Biological API Drug Manufacturing Price by Application (2017-2023)

7 Key Companies Profiled
7.1 Company
7.1.1 Biological API Drug Manufacturing Corporation Information
7.1.2 Biological API Drug Manufacturing Product Portfolio
7.1. CBiological API Drug Manufacturing Production Capacity, Revenue, Price and Gross Margin (2017-2023)
7.1.4 Company’s Main Business and Markets Served
7.1.5 Company’s latest Developments/Updates

8 Biological API Drug Manufacturing Manufacturing Cost Analysis
8.1 Biological API Drug Manufacturing Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Biological API Drug Manufacturing
8.4 Biological API Drug Manufacturing Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Biological API Drug Manufacturing Distributors List
9.3 Biological API Drug Manufacturing Customers

10 Market Dynamics
10.1 Biological API Drug Manufacturing Industry Trends
10.2 Biological API Drug Manufacturing Market Drivers
10.3 Biological API Drug Manufacturing Market Challenges
10.4 Biological API Drug Manufacturing Market Restraints

11 Production and Supply Forecast
11.1 Global Forecasted Production of Biological API Drug Manufacturing by Region (2023-2028)
11.2 North America Biological API Drug Manufacturing Production, Revenue Forecast (2023-2028)
11.3 Europe Biological API Drug Manufacturing Production, Revenue Forecast (2023-2028)
11.4 China Biological API Drug Manufacturing Production, Revenue Forecast (2023-2028)
11.5 Japan Biological API Drug Manufacturing Production, Revenue Forecast (2023-2028)

12 Consumption and Demand Forecast
12.1 Global Forecasted Demand Analysis of Biological API Drug Manufacturing
12.2 North America Forecasted Consumption of Biological API Drug Manufacturing by Country
12.3 Europe Market Forecasted Consumption of Biological API Drug Manufacturing by Country
12.4 Asia Pacific Market Forecasted Consumption of Biological API Drug Manufacturing by Region
12.5 Latin America Forecasted Consumption of Biological API Drug Manufacturing by Country

13 Forecast by Type and by Application (2023-2028)
13.1 Global Production, Revenue and Price Forecast by Type (2023-2028)
13.1.1 Global Forecasted Production of Biological API Drug Manufacturing by Type (2023-2028)
13.1.2 Global Forecasted Revenue of Biological API Drug Manufacturing by Type (2023-2028)
13.1.3 Global Forecasted Price of Biological API Drug Manufacturing by Type (2023-2028)
13.2 Global Forecasted Consumption of Biological API Drug Manufacturing by Application (2023-2028)
13.2.1 Global Forecasted Production of Biological API Drug Manufacturing by Application (2023-2028)
13.2.2 Global Forecasted Revenue of Biological API Drug Manufacturing by Application (2023-2028)
13.2.3 Global Forecasted Price of Biological API Drug Manufacturing by Application (2023-2028)

14 Research Finding and Conclusion

15 Methodology and Data Source
15.1 Methodology/Research Approach
15.1.1 Research Programs/Design
15.1.2 Market Size Estimation
15.1.3 Market Breakdown and Data Triangulation
15.2 Data Source
15.2.1 Secondary Sources
15.2.2 Primary Sources
15.3 Author List
15.4 Disclaimer

Continued….

Purchase this report (Price 5600 USD for a single-user license) -https://www.360marketupdates.com/purchase/21938964

About Us:

360 Market Updates is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Market Updates, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:
Web:https://360marketupdates.com
Email: sales@360marketupdates.com
Organization: 360 Market Updates
Phone: +44 20 3239 8187/ +14242530807

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Biological API Drug Manufacturing Market 2023 In-Depth Insights and Business Scenario, by Analysts Certification 2028 | Newst 121 Pages Report

COMTEX_419063197/2598/2022-11-16T22:51:28

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Wed, 16 Nov 2022 21:49:00 -0600 en-US text/html https://www.marketwatch.com/press-release/biological-api-drug-manufacturing-market-2023-in-depth-insights-and-business-scenario-by-analysts-certification-2028-newst-121-pages-report-2022-11-16
Killexams : Brains Bio Receives NSF’s First CBD Certification for EU GMP CBD API

The independent, third-party certification confirms that the company’s facility and EU GMP CBD products have attained NSF Certified for Sport® certification

VANCOUVER, British Columbia, Nov. 22, 2022 (GLOBE NEWSWIRE) — Brains Bioceutical Corp (“Brains Bio” or the “Company”), a global leader in EU GMP grade Cannabidiol (CBD) has received NSF GMP certification (NSF/ANSI 173, Section 8) for its EU GMP manufacturing facility in the UK. Cannabidiol produced from this facility is an NSF certified Dietary Ingredient (NSF/ANSI standard 173) and Raw Ingredient (Guideline 306), validating claims it has been tested for banned substances, heavy metals, microbials and pesticides.

“Brains Bio remains committed to providing quality, certified ingredients that ensure product integrity while meeting market demands. NSF certification reaffirms our commitment to supplying natural and sustainable cannabinoid ingredients in a rapidly growing marketplace,” said Ricky Brar, CEO and Chairperson of Brains Bio. “NSF certification allows us to supply CBD products tested for more than 280 athletically banned substances to our world-class roster of Olympians and athletes around the globe, giving them absolute assurance of purity.”

This verification will allow the company to partner with leading global sports and nutrition brands such as Brain’s deal with the UK’s largest vitamin company. This comes following the latest announcement from the Major League Baseball (MLB) allowing teams to work only with CBD brands which are NSF Certified for Sport®.

Through its wholly-owned subsidiary BSPG Laboratories, Brains has provided EU GMP CBD for clinical research around the globe for over seven years. With EU and UK-validated novel foods applications, the company now has 19 validated finished products in the UK and validation for its isolate across the EU. The company’s portfolio of proprietary formulations includes oils, sprays, topicals, gummies, capsules, water enhancers, and patches. its natural ingredients go through rigorous quality-control processes to ensure they meet the high-quality standards in the industry.

“We’re excited to announce that Brains Bio is the first company in the world to earn certification from NSF for a CBD ingredient,” said John Travis, Technical Manager for NSF Certified for Sport®. “NSF welcomes Brains Bio to the Certified for Sport® program. NSF is committed to protecting and improving human health worldwide. By meeting our rigorous Certified for Sport® requirements, Brains Bio is demonstrating its commitment to clean sport as well as quality, safety and good manufacturing processes.”

To earn NSF certification, Brains Bio completed a rigorous site inspection and ingredient testing process, verifying that good manufacturing practices are in place and its products have been tested for banned substances, pesticides, and heavy metals.

The certified plant-based EU GMP CBD products, manufacturing facility, and related marketing materials of Brains would bear the NSF Ingredient certification to show product manufacturers and brands that the ingredient quality has met rigorous standards. The above-mentioned list of NSF certifications can be found on NSF data base search domain (https://www.nsf.org/certified-products-systems).

Brains Bio’s market-leading position is further enhanced by its pharmaceutical regulatory package, which includes:

  • German DAC monograph compliant.
  • 36-Month stability data.
  • Over 350 commercial batches manufactured with resulting batch consistency and standardization data.
  • Approved IND filings with the US FDA.
  • Non-GMO, Kosher and Halal certified
  • Tested for banned substances by NSF, Informed Choice, and INRS (a WADA-certified lab)

Brains will also work with its partners and manufacturers, including the UK’s largest vitamin company, to supply EU GMP CBD products with NSF-certified ingredients while still meeting some of the highest quality standards, including ICHQ7, EU GMP, non-GMO, organic, and kosher, among others.

For media inquiries, please contact:
[email protected]

For investor relations, please contact:
[email protected]

Follow Brains Bio on Social:
Twitter: @BrainsBio, LinkedIn: @BrainsBio, Instagram: @BrainsPure

ABOUT BRAINS BIOCEUTICAL CORP.
Brains Bioceutical is the leader in evidence-based Phyto-cannabinoid health solutions to enhance life and treatment options for all.

Brains Bio is a leading manufacturer of natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, Brains Bio is strategically positioned to take advantage of the complex regulatory environment, securing its first-mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.

By partnering with industry leaders in the pharmaceutical and nutraceutical industries, Brains Bio is positioned for hyper-growth by leveraging the existing brand equity, resources, and experience of its major partners.

About NSF

NSF is an independent, global organization that facilitates standards development to minimize adverse health effects and protect the environment. With operations in 180 countries, NSF tests and certifies products for the food, water, health sciences, and consumer goods industries. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF is a Pan American Health Organization and a World Health Organization Collaborating Centre on Water Quality, Food Safety, and Medical Device Safety.

Mon, 21 Nov 2022 21:10:00 -0600 GlobeNewswire en-US text/html https://www.digitaljournal.com/pr/brains-bio-receives-nsfs-first-cbd-certification-for-eu-gmp-cbd-api
Killexams : At-Bay Introduces Miscellaneous Professional Liability Insurance Though API Channel with Auto-Quotes for Businesses with Revenue up to $25M

News Highlights

  • One of the highest revenue appetites in industry for online submissions, boasting double digit revenue limit of up to $25M

  • Proprietary API optimized for end-user compatibility, making deployments and management seamless and easy to do

  • Automated quoting capability generates bindable quotes in under two-minutes, with competitive coverage and pricing making MPL by At-Bay a lucrative revenue option for distribution partners

SAN FRANCISCO, December 08, 2022--(BUSINESS WIRE)--At-Bay, the leading insurance provider for the digital age, today announced that its Miscellaneous Professional Liability (MPL) insurance product will now be available via API to wholesale brokers, multi-carrier platform providers, and other distribution partners who service the insurance and small-to-medium sized business community.

Available to all current and new distribution partners, the MPL API boasts the same signature technology that allows for a seamless integration across multiple partner environments. Upon deployment, brokers can get bindable quotes in under two minutes for more than 50 business classes when applying for a policy with limits of up to $2 million. For customers who need up to $5 million in limits, brokers should expect to hear from an underwriter within 48 hours.

"Our approach to MPL has been to take what’s historically been a complex risk for the industry to price for and cover, and turn it into an insurance product that has commercial scalability and a world-class user experience that brokers, insureds, and channel partners can benefit from equally," says At-Bay’s Head of Partnerships, Kristie Felton. "With more than fifty of the most in-demand business industries covered by our current line, our revenue limit is also one of the most competitive in the industry. Now that we have an API in place, adding new classes is our next priority."

API Feature Advantages for Platform Managers

  • Proprietary REST API is modular in design, making it fast to deploy and easy to maintain.

  • Offers multiple endpoints and insurance options for flexible deployment.

  • Seamless integration to build workflows and select marketplace limits.

  • Modular workflow to support quoting, requoting, binding, generating documents, and issuing policies.

  • Provides a quality end-to-end user journey, allowing partners and customers to quote, bind, and have the policy issued all over the API.

At-Bay MPL Product Advantages for Partnership Managers

  • Policies available to businesses with revenue of up to $25 million - which is one of the highest revenue limits in the industry.

  • More than 50 diverse business classes are currently covered, including many that are historically considered complex, such as advertising, property management, and real estate.

  • Automated quoting capability improves the turnaround time on quotes considerably - for quotes under $2 million in limits, users can fill in At-Bay’s application and get a bindable quote in less than two minutes. Policies requiring up to $5 million in limits will go through an additional review by our underwriting team.

For more information on MPL from At-Bay, and to contact our Partnerships Team, go here or email us here.

About At-Bay

At-Bay is the insurance provider for the digital age. By combining world-class technology with industry-leading insurance expertise, At-Bay was designed from the ground up to empower businesses to thrive in the digital world. At-Bay is backed by Acrew Capital, Glilot Capital, the HSB fund of Munich Re Ventures, Icon Ventures, ION Crossover Partners, Khosla Ventures, Lightspeed Venture Partners, M12, entrepreneur Shlomo Kramer, and Qumra Capital. www.at-bay.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005122/en/

Contacts

Jackie Gray, Corporate Communications
At-Bay
jackieg@at-bay.com

Thu, 08 Dec 2022 06:43:00 -0600 en-US text/html https://www.yahoo.com/entertainment/bay-introduces-miscellaneous-professional-liability-130000603.html
Killexams : Brains Bio Receives NSF's First CBD Certification for EU GMP CBD API

Article content

The independent, third-party certification confirms that the company’s facility and EU GMP CBD products have attained NSF Certified for Sport® certification

VANCOUVER, British Columbia, Nov. 22, 2022 (GLOBE NEWSWIRE) — Brains Bioceutical Corp (“Brains Bio” or the “Company”), a global leader in EU GMP grade Cannabidiol (CBD) has received NSF GMP certification (NSF/ANSI 173, Section 8) for its EU GMP manufacturing facility in the UK. Cannabidiol produced from this facility is an NSF certified Dietary Ingredient (NSF/ANSI standard 173) and Raw Ingredient (Guideline 306), validating claims it has been tested for banned substances, heavy metals, microbials and pesticides.

Advertisement 2

This advertisement has not loaded yet, but your article continues below.

Article content

Article content

“Brains Bio remains committed to providing quality, certified ingredients that ensure product integrity while meeting market demands. NSF certification reaffirms our commitment to supplying natural and sustainable cannabinoid ingredients in a rapidly growing marketplace,” said Ricky Brar, CEO and Chairperson of Brains Bio. “NSF certification allows us to supply CBD products tested for more than 280 athletically banned substances to our world-class roster of Olympians and athletes around the globe, giving them absolute assurance of purity.”

This verification will allow the company to partner with leading global sports and nutrition brands such as Brain’s deal with the UK’s largest vitamin company. This comes following the latest announcement from the Major League Baseball (MLB) allowing teams to work only with CBD brands which are NSF Certified for Sport®.

Advertisement 3

This advertisement has not loaded yet, but your article continues below.

Article content

Through its wholly-owned subsidiary BSPG Laboratories, Brains has provided EU GMP CBD for clinical research around the globe for over seven years. With EU and UK-validated novel foods applications, the company now has 19 validated finished products in the UK and validation for its isolate across the EU. The company’s portfolio of proprietary formulations includes oils, sprays, topicals, gummies, capsules, water enhancers, and patches. its natural ingredients go through rigorous quality-control processes to ensure they meet the high-quality standards in the industry.

“We’re excited to announce that Brains Bio is the first company in the world to earn certification from NSF for a CBD ingredient,” said John Travis, Technical Manager for NSF Certified for Sport®. “NSF welcomes Brains Bio to the Certified for Sport® program. NSF is committed to protecting and improving human health worldwide. By meeting our rigorous Certified for Sport® requirements, Brains Bio is demonstrating its commitment to clean sport as well as quality, safety and good manufacturing processes.”

Advertisement 4

This advertisement has not loaded yet, but your article continues below.

Article content

To earn NSF certification, Brains Bio completed a rigorous site inspection and ingredient testing process, verifying that good manufacturing practices are in place and its products have been tested for banned substances, pesticides, and heavy metals.

The certified plant-based EU GMP CBD products, manufacturing facility, and related marketing materials of Brains would bear the NSF Ingredient certification to show product manufacturers and brands that the ingredient quality has met rigorous standards. The above-mentioned list of NSF certifications can be found on NSF data base search domain (https://www.nsf.org/certified-products-systems).

Brains Bio’s market-leading position is further enhanced by its pharmaceutical regulatory package, which includes:

Advertisement 5

This advertisement has not loaded yet, but your article continues below.

Article content

  • German DAC monograph compliant.
  • 36-Month stability data.
  • Over 350 commercial batches manufactured with resulting batch consistency and standardization data.
  • Approved IND filings with the US FDA.
  • Non-GMO, Kosher and Halal certified
  • Tested for banned substances by NSF, Informed Choice, and INRS (a WADA-certified lab)

Brains will also work with its partners and manufacturers, including the UK’s largest vitamin company, to supply EU GMP CBD products with NSF-certified ingredients while still meeting some of the highest quality standards, including ICHQ7, EU GMP, non-GMO, organic, and kosher, among others.

For media inquiries, please contact:
media@brainsbio.com

For investor relations, please contact:
ir@brainsbio.com

Advertisement 6

This advertisement has not loaded yet, but your article continues below.

Article content

Follow Brains Bio on Social:
Twitter: @BrainsBio, LinkedIn: @BrainsBio, Instagram: @BrainsPure

ABOUT BRAINS BIOCEUTICAL CORP.
Brains Bioceutical is the leader in evidence-based Phyto-cannabinoid health solutions to enhance life and treatment options for all.

Brains Bio is a leading manufacturer of natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, Brains Bio is strategically positioned to take advantage of the complex regulatory environment, securing its first-mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.

Advertisement 7

This advertisement has not loaded yet, but your article continues below.

Article content

By partnering with industry leaders in the pharmaceutical and nutraceutical industries, Brains Bio is positioned for hyper-growth by leveraging the existing brand equity, resources, and experience of its major partners.

About NSF

NSF is an independent, global organization that facilitates standards development to minimize adverse health effects and protect the environment. With operations in 180 countries, NSF tests and certifies products for the food, water, health sciences, and consumer goods industries. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF is a Pan American Health Organization and a World Health Organization Collaborating Centre on Water Quality, Food Safety, and Medical Device Safety.

Advertisement

This advertisement has not loaded yet, but your article continues below.

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Mon, 21 Nov 2022 21:35:00 -0600 en-CA text/html https://financialpost.com/globe-newswire/brains-bio-receives-nsfs-first-cbd-certification-for-eu-gmp-cbd-api
Killexams : Brains Bio Receives NSF’s First CBD Certification for EU GMP CBD API

VANCOUVER, British Columbia, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp ("Brains Bio" or the "Company"), a global leader in EU GMP grade Cannabidiol (CBD) has received NSF GMP certification (NSF/ANSI 173, Section 8) for its EU GMP manufacturing facility in the UK. Cannabidiol produced from this facility is an NSF certified Dietary Ingredient (NSF/ANSI standard 173) and Raw Ingredient (Guideline 306), validating claims it has been tested for banned substances, heavy metals, microbials and pesticides.

"Brains Bio remains committed to providing quality, certified ingredients that ensure product integrity while meeting market demands. NSF certification reaffirms our commitment to supplying natural and sustainable cannabinoid ingredients in a rapidly growing marketplace,” said Ricky Brar, CEO and Chairperson of Brains Bio. "NSF certification allows us to supply CBD products tested for more than 280 athletically banned substances to our world-class roster of Olympians and athletes around the globe, giving them absolute assurance of purity."

This verification will allow the company to partner with leading global sports and nutrition brands such as Brain's deal with the UK’s largest vitamin company. This comes following the latest announcement from the Major League Baseball (MLB) allowing teams to work only with CBD brands which are NSF Certified for Sport®.

Through its wholly-owned subsidiary BSPG Laboratories, Brains has provided EU GMP CBD for clinical research around the globe for over seven years. With EU and UK-validated novel foods applications, the company now has 19 validated finished products in the UK and validation for its isolate across the EU. The company’s portfolio of proprietary formulations includes oils, sprays, topicals, gummies, capsules, water enhancers, and patches. its natural ingredients go through rigorous quality-control processes to ensure they meet the high-quality standards in the industry.

“We’re excited to announce that Brains Bio is the first company in the world to earn certification from NSF for a CBD ingredient,” said John Travis, Technical Manager for NSF Certified for Sport®. “NSF welcomes Brains Bio to the Certified for Sport® program. NSF is committed to protecting and improving human health worldwide. By meeting our rigorous Certified for Sport® requirements, Brains Bio is demonstrating its commitment to clean sport as well as quality, safety and good manufacturing processes.”

To earn NSF certification, Brains Bio completed a rigorous site inspection and ingredient testing process, verifying that good manufacturing practices are in place and its products have been tested for banned substances, pesticides, and heavy metals.

The certified plant-based EU GMP CBD products, manufacturing facility, and related marketing materials of Brains would bear the NSF Ingredient certification to show product manufacturers and brands that the ingredient quality has met rigorous standards. The above-mentioned list of NSF certifications can be found on NSF data base search domain (https://www.nsf.org/certified-products-systems).

Brains Bio’s market-leading position is further enhanced by its pharmaceutical regulatory package, which includes:

  • German DAC monograph compliant.
  • 36-Month stability data.
  • Over 350 commercial batches manufactured with resulting batch consistency and standardization data.
  • Approved IND filings with the US FDA.
  • Non-GMO, Kosher and Halal certified
  • Tested for banned substances by NSF, Informed Choice, and INRS (a WADA-certified lab)

Brains will also work with its partners and manufacturers, including the UK’s largest vitamin company, to supply EU GMP CBD products with NSF-certified ingredients while still meeting some of the highest quality standards, including ICHQ7, EU GMP, non-GMO, organic, and kosher, among others.

For media inquiries, please contact:

media@brainsbio.com

For investor relations, please contact:

ir@brainsbio.com

Follow Brains Bio on Social:

Twitter: @BrainsBio, LinkedIn: @BrainsBio, Instagram: @BrainsPure

ABOUT BRAINS BIOCEUTICAL CORP.

Brains Bioceutical is the leader in evidence-based Phyto-cannabinoid health solutions to enhance life and treatment options for all.

Brains Bio is a leading manufacturer of natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, Brains Bio is strategically positioned to take advantage of the complex regulatory environment, securing its first-mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.

By partnering with industry leaders in the pharmaceutical and nutraceutical industries, Brains Bio is positioned for hyper-growth by leveraging the existing brand equity, resources, and experience of its major partners.

About NSF

NSF  is an independent, global organization that facilitates standards development to minimize adverse health effects and protect the environment. With operations in 180 countries, NSF tests and certifies products for the food, water, health sciences, and consumer goods industries. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF is a Pan American Health Organization and a World Health Organization Collaborating Centre on Water Quality, Food Safety, and Medical Device Safety.

Mon, 21 Nov 2022 21:18:00 -0600 en text/html https://lancasteronline.com/sports/mlb/brains-bio-receives-nsf-s-first-cbd-certification-for-eu-gmp-cbd-api/article_446e5ea5-37bc-517a-b66d-a95bd6436de5.html
API-580 exam dump and training guide direct download
Training Exams List